The interim results were so strong in the endometrial trial (ridaforolimus, 3.6 months vs standard of care, 1.9 months) that Merck stopped the trial back in Oct. I'm somewhat surprised they haven't already started the P3 but this announcement will just make for more fun this Summer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.